Sunovion’s SEP-4199 fails to meet primary endpoint in SEP380-201 trial

Sunovion’s SEP-4199 fails to meet primary endpoint in SEP380-201 trial

Source: 
Pharmaceutical Business Review
snippet: 


Sunovion Pharmaceuticals said that a phase 2 study evaluating SEP-4199 as the treatment of major depressive episodes associated with bipolar I disorder (bipolar I depression) failed to meet its primary endpoint.